Clever leaves Holdings Inc. announced that the Company has received the Brazilian GMP certification by ANVISA, the Brazilian Health Regulatory Agency, to manufacture cannabis products for Brazilian patients. Similar to the strict standards of the EU-GMP certification, ANVISA's Brazilian-GMP certification ensures that patients receive the highest quality of medicine by preventing cases of product contamination, variations in compounds concentrations, mix-ups, incorrect labeling, and more. The certification is required for the manufacturing and commercialization of cannabis products in Brazil.

Clever leaves'Colombia facility being awarded Brazilian-GMP marks the company's fifth international official certification and further attests to the high-quality and premium standard practices that Clever leaves upholds in its production. Clever leaves is the first and only medicinal cannabis company globally who has GMP certifications from the EU, Colombia and Brazil. Brazil currently has a population of over 210 million and has a regulatory framework for the use of medical cannabis products authorized under the RDC 327/2019.

In addition to making Clever leaves one of the few cannabis companies outside of Brazil to receive ANVISA's GMP certification, this certification, along with the EU-GMP, will allow Clever leaves to expand operations into new and existing markets throughout the 5 continents that recognize international GMP standards and enable patient access to Clever leaves' high-quality products.